Apotea, Sweden’s largest online pharmacy, is gearing up for an IPO to fuel its expansion and solidify its position in the market. Founded in 2011 by CEO and co-founder Pär Svärdson, the company has seen profitable growth and is now ready to take the next step in its journey.

Svärdson is optimistic about the future, stating that the IPO will provide the company with the resources needed to continue developing and achieving its goal of becoming Sweden’s largest pharmacy. With a focus on speed, affordability, and free shipping, Apotea has established itself as a leader in the industry, catering to the needs of modern consumers.

The IPO will involve a distribution of existing shares, with major shareholders such as Laulima, Alecta Tjänstepension Ömsesidigt, Neudi Kapital, and Creades offering their shares to the public. Laulima, closely associated with Svärdson, intends to retain a significant portion of its shares and remain a long-term investor in the company. The offering will be open to both institutional investors and individual buyers, allowing for a diverse shareholder base.

In the first nine months of the year, Apotea reported a revenue of approximately 4.808 billion SEK, with an operating profit of 213.9 million SEK. The company has set ambitious financial goals, aiming to double its revenue within 4-5 years and achieve a long-term operating margin of 7-8 percent. With a focus on profitable growth, Apotea plans to reinvest its positive cash flow into the business while considering potential dividends for shareholders.

Creades, a key investor in Apotea, currently holds a 5 percent stake in the company, highlighting its confidence in the company’s future prospects. As Apotea prepares for its IPO, stakeholders are eager to see how the company will leverage the capital raised to drive further growth and innovation in the competitive pharmaceutical market.

Overall, Apotea’s upcoming IPO signals a new chapter for the company as it looks to build on its success and expand its reach in the Swedish healthcare sector. With a strong foundation and a clear vision for the future, Apotea is poised to make a significant impact in the industry and deliver value to both investors and customers alike.

Shares: